Noble Financial analyst Robert LeBoyer reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report) today and set a price target of $14.00. The company’s shares closed yesterday at $3.76.
LeBoyer covers the Healthcare sector, focusing on stocks such as MAIA Biotechnology, Inc., Tonix Pharma, and Axcella Health. According to TipRanks, LeBoyer has an average return of -3.4% and a 27.81% success rate on recommended stocks.
MAIA Biotechnology, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $14.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $9.64 and a one-year low of $3.06. Currently, MAIA Biotechnology, Inc. has an average volume of 25.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company’s lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Read More on MAIA:
